Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOB015B for Distal Subungual Onychomycosis
NCT05279846Phase 3Active, not recruiting
- Sponsor
- Moberg Pharma AB
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 2
01
Overview
A Phase 3 trial of MOB-015 in distal subungual onychomycosis (DSO), sponsored by Moberg Pharma AB. Started May 2022; status: active, not recruiting.
02
Drugs
MOB-015
03
Conditions
distal subungual onychomycosis (DSO)
Beyond the preview
Go deeper on NCT05279846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279846.